HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
PTCT
PTC Therapeutics, Inc.
PTCT lost money over the past year, so it has no meaningful PE right now. Analysts expect earnings to recover and profitability to improve, though they disagree widely on how much.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
PTCT Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Under pressure | |
| Under pressure | |
| Strong |
PTCT's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
PTCT PE Valuation
PTCT has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
PTCT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
PTCT has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
PTCT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.93 | — |
| Q3 2026 | -$1.36 | -116% |
| Q2 2026 | -$0.54 | -108% |
| Q1 2026 | -$2.29 | -135% |
| Q4 2025 | $7.78 | +$12.51 |
| Q3 2025 | $8.56 | +$14.51 |
| Q2 2025 | $6.97 | +$13.29 |
| Q1 2025 | $6.51 | +$14.20 |
| Q4 2024 | -$4.73 | +$3.64 |
PTCT has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over PTCT on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
PTCT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $357.8M | +70% |
| Q2 2026 | $360.5M | +102% |
| Q1 2026 | $272.6M | -77% |
| Q4 2025 | $164.7M | -23% |
| Q3 2025 | $211M | +7.2% |
| Q2 2025 | $178.9M | -4.2% |
| Q1 2025 | $1.2B | +460% |
| Q4 2024 | $213.2M | -31% |
PTCT's revenue is recovering but still below its 2025 peak: $358M last quarter, up 70% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 7% | +5.6 points |
| Q2 2026 | 41% | +61 points |
| Q1 2026 | 17% | -66 points |
| Q4 2025 | -43% | +33 points |
| Q3 2025 | 1.4% | +29 points |
| Q2 2025 | -20% | +2 points |
| Q1 2025 | 83% | +104 points |
| Q4 2024 | -76% | -78 points |
PTCT has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over PTCT on cash flow, with more consistent year-over-year improvement.
PTCT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$28M | +$41.8M |
| Q2 2026 | $126.9M | +$186.6M |
| Q1 2026 | -$60.2M | -107% |
| Q4 2025 | -$36.6M | -$2.9M |
| Q3 2025 | -$69.7M | +$7.8M |
| Q2 2025 | -$59.7M | +$4.4M |
| Q1 2025 | $868.4M | +1320% |
| Q4 2024 | -$33.8M | +$72.1M |
PTCT has burned cash in almost every quarter: $2M over the past year, down 100% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over PTCT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
PTCT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -9.3% | -8.5M shares |
| 1 year | -4.2% | -3.6M shares |
| 3 years | +11% | +8.1M shares |
| 5 years | +18% | +12.9M shares |
| Available history | +42% | +24.6M shares |
PTCT has 83M diluted shares, down 4.2% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
PTCT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.1x | Very low |
| Q2 2026 | -2.5x | Net Cash |
| Q4 2025 | -0.8x | Net Cash |
| Q3 2025 | -0.5x | Net Cash |
| Q2 2025 | -1.0x | Net Cash |
| Q1 2025 | -1.6x | Net Cash |
| Q3 2024 | -15.8x | Net Cash |
| Q2 2024 | -51.7x | Net Cash |
PTCT's net debt is less than a year of its operating earnings (EBITDA), after holding more cash than debt a year ago.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
PTCT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 44.2 | Neutral |
| Stochastic | 24.9 | Neutral |
PTCT's weekly RSI is 44 (neutral) and its Stochastic is 25 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
PTCT PE vs Healthcare Sector
| Metric | PTCT | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
PTCT has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
PTCT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $62.4 | 1.5% above |
| 20 week MA | $68.8 | 7.9% below |
| 50 week MA | $70.9 | 11% below |
| 100 week MA | $62.3 | 1.7% above |
| 200 week MA | $49.1 | 29% above |
PTCT has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
PTCT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $48.8 | $65.1 | +33% |
| 2021 | $65.1 | $41.9 | -36% |
| 2022 | $41.9 | $36.5 | -13% |
| 2023 | $36.5 | $27.6 | -24% |
| 2024 | $27.6 | $45.2 | +64% |
| 2025 | $45.2 | $78.6 | +74% |
| 2026 YTD | $78.6 | $63.4 | -19% |
PTCT has the edge over HIMS on returns for 2026, with the stronger performance.